Inhaled vilanterol trifenatate/fluticasone furoate increases maximum diaphragm contraction in severe COPD Source: International Congress 2014 – Clinical physiology and respiratory muscles Year: 2014
Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014
Improvement of the length tension relation in severe COPD with vilanterol trifenatate/fluticasone furoate Source: International Congress 2017 – Management of COPD Year: 2017
Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Severe exacerbations, decline in lung function and inhaled budesonide in asthma Source: Eur Respir J 2007; 30: Suppl. 51, 619s Year: 2007
Pre-exercise inhalation of short-acting ß-agonists (SABA) safely improves exercise performance in severe COPD patients by reducing lung hyperinflation Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002
Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD Source: Annual Congress 2006 - COPD therapy Year: 2006
Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Low-mid dose assessment Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
NVA237, a once-daily anticholinergic, demonstrates sustained bronchodilation and is well tolerated in patients with reversible obstructive airways disease Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Effects of fluticasone and ciclesonide on pulmonary function and airway inflammation in stable mild asthmatics Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Inhaled corticosteroids and growth of airway function in asthmatic children Source: Eur Respir J 2004; 23: 861-868 Year: 2004
The improvements of lung function tests after formoterol administration in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 323s Year: 2004
Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Mid-high dose assessment Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 379s Year: 2004
Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study Source: International Congress 2014 – Asthma and COPD management Year: 2014